Lexeo Therapeutics, Inc. $LXEO Shares Sold by Octagon Capital Advisors LP

Octagon Capital Advisors LP trimmed its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 36.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,100,000 shares of the company’s stock after selling 625,000 shares during the period. Lexeo Therapeutics accounts for about 0.7% of Octagon Capital Advisors LP’s holdings, making the stock its 25th biggest holding. Octagon Capital Advisors LP’s holdings in Lexeo Therapeutics were worth $6,314,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Allworth Financial LP raised its position in Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after purchasing an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after buying an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lexeo Therapeutics in the fourth quarter worth about $37,000. California State Teachers Retirement System grew its stake in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after buying an additional 2,148 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Lexeo Therapeutics by 160.2% in the fourth quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company’s stock valued at $58,000 after buying an additional 3,615 shares in the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on LXEO shares. JPMorgan Chase & Co. reduced their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, June 25th. Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 10th. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Chardan Capital reissued a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Lexeo Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.75.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ LXEO opened at $4.66 on Monday. Lexeo Therapeutics, Inc. has a 1 year low of $3.60 and a 1 year high of $10.99. The firm has a market cap of $365.90 million, a price-to-earnings ratio of -3.21 and a beta of 1.42. The stock’s 50-day simple moving average is $4.75 and its 200-day simple moving average is $6.00.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. As a group, research analysts predict that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current year.

Insider Buying and Selling

In related news, CEO Richard Nolan Townsend sold 25,947 shares of Lexeo Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the sale, the chief executive officer owned 377,817 shares in the company, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the sale, the insider directly owned 82,194 shares in the company, valued at $363,297.48. This represents a 21.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 62,204 shares of company stock valued at $280,089 in the last three months. Corporate insiders own 2.00% of the company’s stock.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.